Taken together, FXR signaling appears to be critical in mediating these effects, emphasizing the potential of puerarin as a therapeutic agent in ameliorating hepatic dysfunction associated with obesity-induced alterations in bile acid metabolism. This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.